Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss

Last updated: October 16, 2026
Sponsor: Tango Therapeutics, Inc.
Overall Status: Active - Recruiting

Phase

1/2

Condition

Brain Cancer

Lung Disease

Neoplasms

Treatment

abemaciclib

TNG456

Clinical Study ID

NCT06810544
TNG456-C101
  • Ages > 18
  • All Genders

Study Summary

This is a first in human study of TNG456 alone and in combination with abemaciclib in patients with advanced or metastatic solid tumors known to have an MTAP loss. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific solid tumor types with a confirmed MTAP loss. The study drug, TNG456, is a selective PRMT5 inhibitor administered orally. The study is planned to treat up to 191 participants.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Has a tumor with a confirmed MTAP loss

  • Is ≥18 years of age at the time of signature of the main study ICF

  • Has had progression or an inadequate response to or is intolerant of the approvedstandard of care therapy, no standard of care therapy exists, or the investigatorhas determined that treatment with the standard of care therapy is not appropriate.

  • Is able to swallow tablets

  • Adequate Organ function/reserve per local labs

  • Negative serum pregnancy test result at screening

  • Has an ECOG performance status score of 0 to 1

  • Has measurable disease based on RECIST v1.1 or a confirmed glioblastoma (IDH-wildtype) with radiographic evidence of disease progression or recurrencedefined by RANO 2.0.

  • Has an ECOG performance score of 0 to 1 or for GBM has a Karnofsky performancestatus score ≥70.

Exclusion

Exclusion Criteria:

  • A female patient is who is pregnant or breastfeeding

  • Has impaired GI function or disease that may significantly alter the absorption oforal study treatment(s)

  • Has an active infection requiring systemic therapy

  • Has received prior treatment with a PRMT5 inhibitor or a MAT2A inhibitor

  • Patients in the expansion receiving the combination therapy that have received priortreatment with a CDK4/6 inhibitor

  • Clinically relevant cardiovascular disease

  • Has a prior or ongoing clinically significant illness may affect the safety of thepatient, impair the assessment of study results or compliance with the protocol

Study Design

Total Participants: 191
Treatment Group(s): 2
Primary Treatment: abemaciclib
Phase: 1/2
Study Start date:
March 24, 2025
Estimated Completion Date:
September 30, 2027

Study Description

This is a Phase 1/2 multi-center, open label study in solid tumor patients who have a confirmed MTAP loss in their tumor. The Phase 1 portion is a dose escalation study of oral TNG456 administered as a single agent and in combination with oral abemaciclib in solid tumor patients with confirmed MTAP loss. In the Phase 2 expansion part of the study, 6 arms defined by confirmed tumor types will enroll in parallel at the RP2D(s) of TNG456 and in combination. In both parts of the study participants who tolerate the drug may continue treatment until disease progression.

Connect with a study center

  • Mayo Clinic Scottsdale

    Scottsdale, Arizona 85259-5452
    United States

    Active - Recruiting

  • University of California, Irvine

    Irvine, California 92686
    United States

    Active - Recruiting

  • University of California Los Angeles

    Los Angeles, California 90995
    United States

    Active - Recruiting

  • University of California at San Francisco

    San Francisco, California 94143-2202
    United States

    Active - Recruiting

  • Sibley Memorial Hospital

    Washington D.C., District of Columbia 20016
    United States

    Active - Recruiting

  • Mayo Clinic Jacksonville

    Jacksonville, Florida 32224
    United States

    Active - Recruiting

  • Northwestern Memorial Hospital

    Chicago, Illinois 60611-2908
    United States

    Active - Recruiting

  • Dana Farber Cancer Institute

    Boston, Massachusetts 02215
    United States

    Active - Recruiting

  • Mayo Clinic Cancer Center

    Rochester, Minnesota 55905-0001
    United States

    Active - Recruiting

  • Memorial Sloan Kettering Cancer Center

    New York, New York 11065
    United States

    Active - Recruiting

  • NYU Langone Health

    New York, New York 10016
    United States

    Active - Recruiting

  • Ohio State University Comprehensive Cancer Center

    Columbus, Ohio 43210
    United States

    Active - Recruiting

  • MD Anderson Cancer Center

    Houston, Texas 77030
    United States

    Active - Recruiting

  • University of Utah, Huntsman Cancer Institute

    Salt Lake City, Utah 84112-5500
    United States

    Active - Recruiting

  • NEXT Virginia

    Fairfax, Virginia 22031
    United States

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.